Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN AND POLYMYXIN B SULFATE.
AMIKIN vs NEOMYCIN AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B sulfate is a cationic detergent that disrupts bacterial cell membrane permeability by interacting with phospholipids, leading to cell death.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
For irrigation of urinary bladder: 1 mL of solution containing 40 mg neomycin and 200,000 units polymyxin B per mL diluted in 1 liter of 0.9% sodium chloride, instilled via continuous irrigation at a rate of 1 liter per 24 hours. For topical use: apply thin layer to affected area 2-4 times daily.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Neomycin: 2-3 hours (normal renal function), prolonged to 24-48 hours in renal impairment; Polymyxin B: 4.5-6 hours (normal renal function), extended significantly in renal failure.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal: ~90-95% (neomycin, polymyxin B) unchanged; fecal: 5-10% (biliary excretion negligible).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic